Eric Aguiar MD Overview

  • Primary Position
  • Partner

  • Primary Industry
  • Healthcare

  • Active Board Seats
  • 4

  • Med. Deal Size

  • Med. Valuation

Eric Aguiar MD General Information

Biography

Dr. Eric Aguiar serves as a Partner at Aisling Capital. He also serves as a Board Member at BridgeBio, Invitae, Biomea Fusion, Garuda Therapeutics, and Eidos Therapeutics. He serves as the Board Observer of PellePharm. Prior to Aisling, he was a partner at Thomas, McNerney, and Partners, a $600 million healthcare-focused venture capital and growth equity fund, from 2007 to 2015. He serves as Director at Eidos Therapeutics. He was a Managing Director of HealthCare Ventures, a healthcare venture capital fund, from 2001 to 2007. He was CEO of Genovo, Inc., a biopharmaceutical company that specialized in gene delivery and gene regulation. He was also the executive director of TheraTech, Inc. He was a Vice President and Managing Director of Philadelphia Ventures from 1992 to 1997. His prior board service includes Amarin, CardioKine, Biohaven (acquired by Pfizer), Metaphore (merged with ActivBiotics), Oriel Therapeutics (acquired by Novartis), SkinMedica, Virdante Pharmaceuticals (acquired by Momenta) and 3-D Pharmaceuticals (acquired by Johnson & Johnson). He serves as Emeritus Advisor to Tufts University School of Medicine and is a member of the Council on Foreign Relations. He received his M.D. with honors from Harvard Medical School and his B.A. with honors from Cornell University as a College Scholar. He was also a Luce Fellow and is a Chartered Financial Analyst.

Contact Information

Primary Position
Education
Harvard Medical School, MD (Doctor of Medicine)
Cornell University, BA (Bachelor of Arts) Honors
Gender
Male
Email
ea
Phone
+1 (212)
Address
  • 489 Fifth Avenue
  • Floor 10
  • New York, NY 10017
  • United States
+1 (212)

Eric Aguiar MD Positions (1)

Firm name Firm type Title Location Industry Since
Aisling Capital Investor Partner New York, NY Venture Capital

Eric Aguiar MD Board Seats (4)

Company Industry Ownership Status Financing Status Location Since
Biomea Fusion Drug Discovery Publicly Held Formerly VC-backed Redwood City, CA
BridgeBio Pharma Biotechnology Publicly Held Formerly VC-backed Palo Alto, CA
Garuda Therapeutics Drug Discovery Privately Held (backing) Venture Capital-Backed Cambridge, MA
PellePharm Drug Discovery Privately Held (backing) Venture Capital-Backed San Francisco, CA

Eric Aguiar MD Lead Partner on Deals (15)

Company Deal Date Deal Type Deal Size Deal Status Industry Location
Garuda Therapeutics 24-Jan-2023 Early Stage VC (Series B) Completed Drug Discovery Cambridge, MA
Garuda Therapeutics 07-Sep-2021 Completed Drug Discovery Cambridge, MA
Biomea Fusion 23-Dec-2020 Completed Drug Discovery Redwood City, CA
BridgeBio Pharma 23-Jan-2019 Completed Biotechnology Palo Alto, CA
BridgeBio Pharma 10-Apr-2018 Completed Biotechnology Palo Alto, CA
Eidos Therapeutics 05-Apr-2018 Completed Drug Discovery San Francisco, CA
Biohaven 16-Feb-2017 Completed Drug Discovery Tortola, VI
BridgeBio Pharma 26-Mar-2016 Completed Biotechnology Palo Alto, CA
Invitae 13-Oct-2014 Later Stage VC (Series F) Completed Clinics/Outpatient Services San Francisco, CA
Invitae 10-Dec-2013 Later Stage VC (Series E) Completed Clinics/Outpatient Services San Francisco, CA

Eric Aguiar MD Network (218)

Board Members (84)

Name Company Representing Location From
Anders Hove MD POGO Automatic Venrock Fremont, CA
John Childs Biohaven Self Tortola, VI
PellePharm BridgeBio Pharma San Francisco, CA
BridgeBio Pharma BridgeBio Pharma Palo Alto, CA
Eidos Therapeutics Self San Francisco, CA

Portfolio Executives (118)

Name Company Role Deal date Location
James Desiderio Ph.D Garuda Therapeutics Chief Regulatory Officer 24-Jan-2023 Cambridge, MA
David DiGiusto Ph.D Garuda Therapeutics Chief Technology Officer 24-Jan-2023 Cambridge, MA
Garuda Therapeutics Chief Financial Officer 24-Jan-2023 Cambridge, MA
Garuda Therapeutics Co-Founder 24-Jan-2023 Cambridge, MA
Garuda Therapeutics Co-Founder 24-Jan-2023 Cambridge, MA

Fund Team Members (16)

Name Investor Fund Fund Location
Alex Zisson Thomas McNerney & Partners Thomas McNerney & Partners Fund Stamford, CT
Alex Zisson Thomas McNerney & Partners Thomas McNerney & Partners II Stamford, CT
HealthCare Ventures Cambridge, MA
HealthCare Ventures Cambridge, MA
Aisling Capital New York, NY

Eric Aguiar MD Affiliated Funds (5)

Fund Investor Fund Type Status Vintage Size Dry Powder IRR IRR Quartile
Thomas McNerney & Partners Fund Thomas McNerney & Partners Venture - General Liquidated 2003
HealthCare Ventures VIII HealthCare Ventures Venture - General Closed 2005
Thomas McNerney & Partners II Thomas McNerney & Partners Venture - General Liquidated 2006
Aisling Capital IV Aisling Capital Venture Capital - Later Stage Fully Invested 2016
Aisling Capital V Aisling Capital Venture Capital - Later Stage Closed 2019

Eric Aguiar MD FAQs

  • Who is Eric Aguiar MD?

    Dr. Eric Aguiar serves as a Partner at Aisling Capital.

  • How much does Eric Aguiar MD typically invest?

    Eric Aguiar MD's median deal size is .

  • What is Eric Aguiar MD’s main position?

    Eric Aguiar MD’s primary position is Partner.

  • What are the contact details for Eric Aguiar MD?

    Eric Aguiar MD’s email address is ea and his phone number is +1 (212) .

  • How many active board seats does Eric Aguiar MD hold?

    Eric Aguiar MD holds 4 board seats including Biomea Fusion, BridgeBio Pharma, Garuda Therapeutics, and PellePharm.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »